The AcT Trial: Tenecteplase vs Alteplase for Acute Ischemic Stroke
RebelEM
FEBRUARY 1, 2024
What they Did : Investigator-initiated, Multicenter, Parallel-ground, Open-label, Registry-linked, Randomized, Controlled, Non-Inferiority trial 22 Canadian Primary and Comprehensive Stroke Centers from December 2019 to January 2022 Eligible ischemic stroke patients randomized 1:1 to receive intravenous tenecteplase (0.25 vs Alteplase 34.8%
Let's personalize your content